Catastrophic Elephant Man Drug Trial Victims Injected Recklessly

Catastrophic Elephant Man Drug Trial Victims Injected Recklessly

Experts allege that victims of the terrible 'Elephant Man' clinical trial were given the test drug injections at a 'reckless' rate.

The drug, a monoclonal antibody was TGN 1412 that is supposed to fight leukaemia, multiple sclerosis and rheumatoid arthritis. Confidential documents have revealed that the victims had been injected 15 times faster than when given to monkeys in animal studies.

Scientists claim that this 'reckless' mistake probably explained the disastrous reaction to the drug that has left volunteers fighting for their lives.

The six young men who has volunteered for the trial were all fit and healthy before signing up for the March trial at Northwick Park Hospital in North-West London. After the injection they suffered a host of side-effects, including pain, vomiting and organ failure.

---

J-Hawk gridders fall to Red Raiders

J-Hawk gridders fall to Red Raiders

However, the J-Hawks were not able to contain the passing combination of Red Raiders cousins Brian and Jared Foran much past the opening quarter.The Forans hooked up for four touchdowns in a 49-6 victory over Joliet.The J-Hawks fought to a 6-all tie with the Red Raiders through the first quarter. Joliet's lone score came on a 47-yard scamper by sophomore running back Cody Bennett. Winifred's first period score was a 21-yard TD reception by receiver Brian Foran from quarterback Jared Foran.In the second quarter, Winifred broke open the game when the Forans connected for touchdown scores of 24 yards and 11 yards. Also, Spencer Bold added a 5-yard touchdown run to put the Red Raiders ahead 28-6 at halftime.Winifred padded its lead in the second half with three more scores. Brian Foran pulled in a 30-yard TD strike from Jared Foran and Dustan Kinkelaar had an 8-yard romp to pay dirt in the third quarter.

---

Why more rheumatoid arthritis in women

Why more rheumatoid arthritis in women

NEW YORK, Sept. 28 (UPI) -- Males exert an influence on rheumatoid arthritis mechanisms, mainly the production of anti-cyclic citrullinated peptides antibodies, says a U.S. study.

Researchers the University of California studied 1,004 affected members of 467 Caucasian families within which two or more siblings met the American College of Rheumatology criteria for rheumatoid arthritis.

Each patient was examined for joint tenderness, completed a Health Assessment Questionnaire and underwent radiographs of the hands and wrists to evaluate bone erosions. Each patient was also genotyped for markers and tested for two hallmarks of the disease: rheumatoid factor and antibodies to cyclic citrullinated peptides.

Although male patients had significantly later onset of rheumatoid arthritis, they showed more signs of erosive disease, were more likely to test positive for rheumatoid factor and antibodies to cyclic citrullinated peptides.

---

Does a coxib-associated thrombotic risk limit the clinical use of ...

Does a coxib-associated thrombotic risk limit the clinical use of ... Non-steroidal anti-inflammatory agents (NSAIDs) and selective cyclooxygenase (COX-2) inhibitors (coxibs) are commonly used as analgesic and anti-inflammatory agents. Selective COX-2 inhibitors or coxibs were primarily developed as a response to the gastrointestinal toxicity of conventional NSAIDs but may have other side effects. Currently available data suggests definite prothrombotic risk with the coxibs, and the magnitude of risk may vary with individual agents. Based on available data, coxibs should be restricted to use as 2nd-line, possibly as 3rd-line, agents for carefully chosen patients and randomized trials versus placebo or an accepted comparator must be performed to define the overall safety profile in diverse patient populations. The recently announced Prospective Randomized Evaluation of Celecoxib Integrated Safety vs.

Rheumatoid arthritis: an update

Rheumatoid arthritis: an update Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology, characterised by symmetric, erosive synovitis and, in some cases, extra-articular involvement. Most patients experience a chronic fluctuating course of disease that, despite therapy, may result in progressive joint destruction, deformity, disability, and even premature death. Active and persistent joint inflammation begets joint damage and functional limitation. If not treated quickly, as many as 80% of patients will develop erosions in their joints in the first two years after RA begins. If the condition is left untreated, over 50% of patients have to stop work within five to ten years of its onset. RA is estimated to affect 1% of the adult population. It results in more than 9 million physician visits and more than 250,000 hospitalisations per year.

Biologics Continue to Drive Strong Growth in Rheumatoid Arthritis ...

Biologics Continue to Drive Strong Growth in Rheumatoid Arthritis ...

The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. Total sales of these products are expected to reach approximately $10 billion in 2006, according to a new report from Arrowhead Publishers entitled Rheumatoid Arthritis: Market Trends and R&D Insights.

MINNEAPOLIS (PRWEB) September 21, 2006 -- The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. Total sales of these products are expected to reach approximately $10 billion in 2006, according to a new report from Arrowhead Publishers entitled Rheumatoid Arthritis: Market Trends and R&D Insights.

---